PFD Management Shares Update PFD/iOI’s FIH Implant

PFD/iOI announces it has cleared the final hurdles in order to move ahead with its First-In-Human implant of its RAD/iKnee technology.

PFD Management Shares Q123 Clinical Progress and Update On CassdermaRx

The FDA and HHS release report discussing the need for better care protocols for patients suffering from chronic wound issues. This support PFD’s efforts with CassdermaRx, one of the medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.

PFD iOI Announces Update On The iKnee Comfort Study And The Path Forward

PFD/iOrthopedics, Inc. (PFD/iOI) has announced further details on its upcoming iKnee Comfort Study.

PFD iOI Announces Updates On The RAD/iKnee Lab Installation

PFD/iOI has released an update on the installation of its ARBURG Freeformer 300-3X 3D printer into the PFD/iOI RAD iKnee Lab at its Los Angeles facility.

PFD iOI Announces Acquisition of Arburg Freeformer 300-3X For Production Of iKnee

PFD/iOI has announced the purchase of the Arburg Freeformer 300-3X 3D printer to start prototype development and manufacture of its iKnee technology. The printer is to be installed at PFD/iOI’s new clean room lab at its Los Angeles facility.

PFD Management Shares End of Year HHS Public Access Author Manuscript Recognition from CassdermaRx

The FDA and HHS release report discussing the need for better care protocols for patients suffering from chronic wound issues. This support PFD’s efforts with CassdermaRx, one of the medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.

PFD Management Shares NKC End-Of-Year Development Report

PFD is proud to share this end-of-year update on Neuro-Kinesis Corporation which is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.

PFD Management Opportunity Fund 3001 Press Release November 15, 2022

PFD is proud to share Neuro-Kinesis Corporation’s fourth quarter 2023 update on it Huygens™ Catheter and Proteus™ Robotic Arm Technologies. this end-of-year update on Neuro-Kinesis Corporation is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.

PFD/iOI Release Update On Their Resilient Arthroplasty Device (RAD) Technology

PFD is pleased to share this updates on its PFD/iOi venture. This includes information of the latest design enhancements by our engineering team for the Resilient Arthroplasty Device – iKnee. as well as information the finalized prototype design, and the initial Proof of Concept with First In Human implant and the launch of the iKnee Comfort Study.

NKC Release Third Quarter Development Report on the Huygens – Proteus™ Robotic Arm Surgical Platform

Neuro-Kinesis Corporation has released its Third-Quarter Development Report on its Huygens™ Catheter and Proteus™ Robotic Arm Technologies. which is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio. The report includes information on the company’s application for Institutional Animal Care and Use Committee Approval (IACUC) for its upcoming animal studies as well as its agreement with Abbott/St. Jude for use of its EnSite NavX System in the NKC Operating Suite.

PFDMOF3001 News

The following articles and press releases are to provide information on the current status of the PFDMOF3001 Opportunity Fund as well as the related technology companies in the portfolio.

 

If you have any questions regarding any information you find here, please contact us at: info@PFDCap.com

NKC Announces Upcoming Animal Study for Clinical Validation of its Huygens™ – Proteus™ Robotic Arm Surgical Platform

NKC Announces Upcoming Animal Study for Clinical Validation of its Huygens™ – Proteus™ Robotic Arm Surgical Platform

PFD shares this press release from Neuro-Kinesis Corporation, one of the medical technology comanies in its PFDMOF3001 Opportunity Fund portfolio which discusses the NKC’s announcement of two upcoming studies to be performed at the Technion Institute in Israel and at Sandia National Laboratories. Each of these studies are being done to validate the technology behind its Huygens™ Catheter platform.

Introducing Dr. Daniel Rastein, Cassderma RX and Castle IRB

Introducing Dr. Daniel Rastein, Cassderma RX and Castle IRB

In this release, PFD shares an update on Dr. Daniel Rastein, MD, MPH who is the Founder & CEO of Cassderma RX, one of the portfolio companies in the PFDMOF3001 Opportunity Fund. Dr . Rastein has been retained by the PFD team to coordinate the Institutional Review Board Sponsored by Advarra for the PFD/iOrthopedics INC new orthopedic Resilient Arthroplasty Device (RAD) referred to as the iKnee,

Phase One Development of Huygens™ Smart Catheter & Proteus™ Robotic Platform Completed

Phase One Development of Huygens™ Smart Catheter & Proteus™ Robotic Platform Completed

PFD is pleased to share this press release from Neuro-KInesis, Corp. (NKC), one of the medical technology companies in the PFDMOF3001 Opportunity Fund. In the release NKC announced they have completed the Phase One development for their new Huygens™ Smart Catheter and Proteus™ Robotic Arm platform as well as five other strategic goals towards its efforts to bring its patented EP Catheter Mapping and Guidance Technology to the Electrophysiology marketplace.

Managing Medical Receivables In Healthcare

Managing Medical Receivables In Healthcare

In this article PFD shares important information on what Medical Receivables (MR) are and why careful management of these assets is the lifeblood of any medical practice. PFD Capital Partners, LLC not only is in the business of helping healthcare providers in removing difficult to collect MR Personal Injury claims from the ledgers, but we also work to help medical professionals in understanding suggested best practice ideas for streamlining the PR process.

The Need For Greater Transparancy In Medical Receivable Funding

The Need For Greater Transparancy In Medical Receivable Funding

In this articles, PFD shares some important information on how the rise in medical receivables financing has created many bad actors in the space and why the importance of making sure the company you decide to do business with practices the highest ethical standards and offers the greatest transparency on how it does business.

Creating A Method For Assessing Recovery From Orthopedic Knee Treatment

Creating A Method For Assessing Recovery From Orthopedic Knee Treatment

PFD share a recent study by researchers from the University of Seville and the University of Cadiz in Spain indicates that there is currently no standardized methodology for qualitative and quantitative for assessing the recovery of patients who have undergone orthopedic knee treatment. This relates to the work being done by PFD/iOi in creating its Resilient Arthroplasty Device known as the iKnee.